Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.

The informed road map to prevention of Alzheimer Disease: A call to arms

Open access
McDade, Eric, Llibre-Guerra, Jorge J., Holtzman, David M., Morris, John C., Bateman, Randall J. · 2021 · Molecular Neurodegeneration

Abstract

Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive decline and dementia onset by intervening before significant neuronal damage occurs. In recent years, the first AD prevention trials have launched and are yielding important findings on the biology of targeting asymptomatic AD pathology. However, there are limitations that impact the design of these prevention trials, including the translation of animal models that recapitulate key stages and multiple pathological aspects of the human disease, missing target validation in asymptomatic disease, uncertain causality of the association of pathophysiologic changes with cognitive and clinical symptoms, and limited biomarker validation for novel targets. The field is accelerating advancements in key areas including the development of highly specific and quantitative biomarker measures for AD pathology, increasing our understanding of the course and relationship of amyloid and tau pathology in asymptomatic through symptomatic stages, and the development of powerful interventions that can slow or reverse AD amyloid pathology. We review the current status of prevention trials and propose key areas of needed research as a call to basic and translational scientists to accelerate AD prevention. Specifically, we review (1) sporadic and dominantly inherited primary and secondary AD prevention trials, (2) proposed targets, mechanisms, and drugs including the amyloid, tau, and inflammatory pathways and combination treatments, (3) the need for more appropriate prevention animal models and experiments, and (4) biomarkers and outcome measures needed to design human asymptomatic prevention trials. We conclude with actions needed to effectively move prevention targets and trials forward.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-021-00467-y

Cites

169 of 169 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A brief history of AD prevention trial development
Fig. 1 A brief history of AD prevention trial developmentCC BY · PubMed Central
Fig. 2 Alzheimer’s disease prevention trials and targets: Prevention trials and target agents for treatment of Alzheimer’s disease in 2020 (from ClinicalTrials.gov as of August 24, 2020). The inner ring shows prevention trials agents; the outer ring presents lifestyle prevention trials. AD therapeutics interventions were classified according with the terminology of the Common Alzheimer’s and Related Dementias Research Ontology (CADRO). Lifestyle interventions (N = 18), Drug Targets (N = 37)
Fig. 2 Alzheimer’s disease prevention trials and targets: Prevention trials and target agents for treatment of Alzheimer’s disease in 2020 (from ClinicalTrials.gov as of August 24, 2020). The inner ring shows prevention trials agents; the outer ring presents lifestyle prevention trials. AD therapeutics interventions were classified according with the terminology of the Common Alzheimer’s and Related Dementias Research Ontology (CADRO). Lifestyle interventions (N = 18), Drug Targets (N = 37)CC BY · PubMed Central
Fig. 3 Timing of AD prevention trials related to core pathology and symptom onset
Fig. 3 Timing of AD prevention trials related to core pathology and symptom onsetCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 169 references

Research works printed but not linked: 1

  1. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis Class of Evidence Criteria for rating therapeutic and diagnostic studies. Neurology. 2019; https://doi.org/10.1212/WNL.0000000000008081. · DOI · Paper page

Cited by

See all 90

Metadata

Authors
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Bateman, Randall J.
Venue
Molecular Neurodegeneration
Published
2021-07-21
Volume
16
Issue
1
Pages
49-49
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3183805246
Cited by
89
References
169
Citations by year
2026: 5 · 2025: 12 · 2024: 24 · 2023: 25 · 2022: 21 · 2021: 2
FWCI
2.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute on Aging (U01AG042791, R1AG046179, R01/R56 AG053267, U01AG059798)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, Alzheimer's disease prevention, prevention trials, amyloid pathology, tau pathology, biomarkers, animal models, primary prevention, secondary prevention, anti-inflammatory therapy, combination therapy, cognitive decline, dementia onset
MeSH terms
Alzheimer Disease, Animals, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The informed road map to prevention of Alzheimer Disease: A call to arms. https://app.cochat.ai/papers/10.1186/s13024-021-00467-y
The paper
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021). The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00467-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.